Scientists have created a high-speed method to generate thousands of different, small, stable proteins from scratch that can be custom-designed to bind to specific therapeutic targets.
These computer-designed proteins, which did not previously exist in nature, combine the stability and bioavailability of small molecule drugs with the specificity and potency of larger biologics.
"These mini-protein binders have the potential of becoming a new class of drugs that bridge the gap between small molecule drugs and biologics. Like monoclonal antibodies, they can be designed to bind to targets with high selectivity, but they are more stable and easier to produce and to administer," said the research lead.
The method used a computer platform, called Rosetta, developed by the authors. They designed thousands of short proteins, about 40 amino acids in length, that the Rosetta program predicted would bind tightly to the molecular target.
Because of their small size, these short proteins tend to be extremely stable. They can be stored without refrigeration. They also are more easily administered than large protein drugs, such as monoclonal antibodies.
Previously, such short, protein-binder drugs were typically re-engineered versions of naturally occurring proteins. These, however, tended not to be significantly better than monoclonal antibodies.
Because these mini-proteins binders are original designs, they can be tailored to fit their targets much more tightly and are simpler to modify and refine.
In this study, the researchers sought to design two sets of these proteins: one set that would prevent the influenza virus from invading cells and another that would bind to and neutralize a deadly nerve toxin from botulism. This toxin is considered a potential bioweapon.
The computer modeling identified the amino-acid sequences of thousands of short proteins that would fit into and bind to the influenza and botulinum targets. The researchers created short pieces of DNA that coded each of these proteins, grew the proteins in yeast cells, and then looked at how tightly they bound to their targets. The targets were Influenza H1 hemagglutinin and botulinum neurotoxin B.
All told, the method allowed them to design and test 22,660 proteins in just a few months. More than than two-thousand of them bound to their targets with high affinity.
Evaluation of the best candidates found that the anti-influenza proteins neutralized viruses in cell culture and other designed proteins prevented the botulinum toxin from entering brain cells.
A nasal spray containing one of the custom-designed proteins completely protected mice from the flu if administered before or as much as 72 hours after exposure. The protection that the treatment provides equaled or surpassed that seen with antibodies, the researchers report.
Testing of a subset of the proteins showed that they were extremely stable and, unlike antibodies, did not become inactivated by high temperatures. The small proteins also triggered little or no immune response, a problem that often renders larger protein drugs ineffective.
https://www.nature.com/nature/journal/vaop/ncurrent/full/nature23912.html
Latest News
Microfluidic systems resemb…
By newseditor
Posted 11 May
Neurotransmitter classifica…
By newseditor
Posted 11 May
Uncovering the secret of lo…
By newseditor
Posted 10 May
A cubic-millimeter fragment…
By newseditor
Posted 10 May
mtDNA transcription Inhibit…
By newseditor
Posted 09 May
Other Top Stories
The reward system synapses mature poorly in autism
Read more
Neonatal hypoxia affects learning and neuronal firing!
Read more
What doesn't kill you makes you stronger!
Read more
Could vitamin B3 treat acute kidney injury?
Read more
MicroRNA (miRNA) misregulation in Huntington's disease
Read more
Protocols
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Parasympathetic neurons der…
By newseditor
Posted 07 May
Non-invasive measurements o…
By newseditor
Posted 05 May
A validation strategy to as…
By newseditor
Posted 04 May
Publications
Vascular network-inspired f…
By newseditor
Posted 11 May
Neurotransmitter classifica…
By newseditor
Posted 11 May
Forward programming human p…
By newseditor
Posted 10 May
Cyclophilin A supports tran…
By newseditor
Posted 10 May
Sortases: structure, mechan…
By newseditor
Posted 10 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar